MA38974A1 - Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate - Google Patents

Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate

Info

Publication number
MA38974A1
MA38974A1 MA38974A MA38974A MA38974A1 MA 38974 A1 MA38974 A1 MA 38974A1 MA 38974 A MA38974 A MA 38974A MA 38974 A MA38974 A MA 38974A MA 38974 A1 MA38974 A1 MA 38974A1
Authority
MA
Morocco
Prior art keywords
dosage forms
morpholin
triazol
pyrazol
pyrimidin
Prior art date
Application number
MA38974A
Other languages
English (en)
Other versions
MA38974B2 (fr
Inventor
Klaus Benke
Heike Neumann
Michael Formell
Gabriele Winter
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49356354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38974(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MA38974A1 publication Critical patent/MA38974A1/fr
Publication of MA38974B2 publication Critical patent/MA38974B2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

L'invention concerne des formes galéniques pharmaceutiques pour administration orale contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate (principe actif (i). Selon l'invention, le principe actif (i) est libéré. L'invention concerne également un procédé de production desdites formes galéniques, leur utilisation comme médicament, ainsi que leur utilisation pour la prophylaxie, la prophylaxie secondaire ou le traitement de maladies, en particulier les maladies cardiovasculaires, l'insuffisance cardiaque, l'anémie, les maladies rénales chroniques et l'insuffisance rénale.
MA38974A 2013-10-17 2014-10-13 Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate MA38974B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13189145 2013-10-17
PCT/EP2014/071855 WO2015055564A1 (fr) 2013-10-17 2014-10-13 Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate

Publications (2)

Publication Number Publication Date
MA38974A1 true MA38974A1 (fr) 2017-05-31
MA38974B2 MA38974B2 (fr) 2020-11-30

Family

ID=49356354

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38974A MA38974B2 (fr) 2013-10-17 2014-10-13 Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate

Country Status (35)

Country Link
US (1) US9827198B2 (fr)
EP (1) EP3057580B1 (fr)
JP (1) JP6525979B2 (fr)
KR (1) KR102330953B1 (fr)
CN (1) CN105636580B (fr)
AP (1) AP2016009135A0 (fr)
AR (1) AR098064A1 (fr)
AU (1) AU2014336389B2 (fr)
BR (1) BR112016007588A2 (fr)
CA (1) CA2927437C (fr)
CL (1) CL2016000857A1 (fr)
CU (1) CU24515B1 (fr)
DK (1) DK3057580T3 (fr)
DO (1) DOP2016000078A (fr)
EA (1) EA032932B1 (fr)
ES (1) ES2868228T3 (fr)
GT (1) GT201600072A (fr)
HR (1) HRP20210691T1 (fr)
HU (1) HUE054107T2 (fr)
IL (1) IL244933B (fr)
JO (1) JO3645B1 (fr)
LT (1) LT3057580T (fr)
MA (1) MA38974B2 (fr)
MX (1) MX2016004628A (fr)
MY (1) MY190202A (fr)
NI (1) NI201600054A (fr)
PE (1) PE20160669A1 (fr)
PH (1) PH12016500716A1 (fr)
SA (1) SA516370940B1 (fr)
SI (1) SI3057580T1 (fr)
TN (1) TN2016000135A1 (fr)
TW (1) TWI746418B (fr)
UA (1) UA119855C2 (fr)
UY (1) UY35784A (fr)
WO (1) WO2015055564A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3845230B1 (fr) * 2018-08-31 2023-07-12 Astellas Pharma Inc. Composition pharmaceutique pour administration par voie orale

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006050516A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dihydropyrazolone und ihre Verwendung
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
DE102010044131A1 (de) * 2010-11-18 2012-05-24 Bayer Schering Pharma Aktiengesellschaft Substituiertes Natrium-1H-pyrazol-5-olat

Also Published As

Publication number Publication date
CU24515B1 (es) 2021-05-12
MY190202A (en) 2022-04-04
AU2014336389B2 (en) 2020-01-30
WO2015055564A1 (fr) 2015-04-23
GT201600072A (es) 2018-12-19
JO3645B1 (ar) 2020-08-27
PH12016500716B1 (en) 2016-06-20
TN2016000135A1 (en) 2017-10-06
NI201600054A (es) 2016-09-21
LT3057580T (lt) 2021-04-12
PE20160669A1 (es) 2016-08-04
SI3057580T1 (sl) 2021-07-30
CA2927437A1 (fr) 2015-04-23
SA516370940B1 (ar) 2019-11-20
UA119855C2 (uk) 2019-08-27
CU20160048A7 (es) 2016-10-28
EA201690788A1 (ru) 2016-09-30
TWI746418B (zh) 2021-11-21
ES2868228T3 (es) 2021-10-21
MX2016004628A (es) 2016-08-01
IL244933B (en) 2020-11-30
BR112016007588A2 (pt) 2017-09-12
JP6525979B2 (ja) 2019-06-05
JP2016538256A (ja) 2016-12-08
KR102330953B1 (ko) 2021-11-26
KR20160068784A (ko) 2016-06-15
CN105636580A (zh) 2016-06-01
AU2014336389A1 (en) 2016-05-12
AP2016009135A0 (en) 2016-04-30
AR098064A1 (es) 2016-04-27
HRP20210691T1 (hr) 2021-06-11
EA032932B1 (ru) 2019-08-30
DK3057580T3 (da) 2021-05-10
EP3057580A1 (fr) 2016-08-24
CA2927437C (fr) 2022-06-28
CN105636580B (zh) 2020-03-31
IL244933A0 (en) 2016-05-31
US9827198B2 (en) 2017-11-28
UY35784A (es) 2015-05-29
NZ718063A (en) 2021-06-25
HUE054107T2 (hu) 2021-08-30
US20160256394A1 (en) 2016-09-08
PH12016500716A1 (en) 2016-06-20
TW201607568A (zh) 2016-03-01
DOP2016000078A (es) 2016-08-15
MA38974B2 (fr) 2020-11-30
CL2016000857A1 (es) 2016-11-25
EP3057580B1 (fr) 2021-02-24

Similar Documents

Publication Publication Date Title
MA37405A1 (fr) Composés hétérocyclyle
PH12016500531B1 (en) Compound inhibiting activities of btk and/or jak3 kinases
MA35348B1 (fr) 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides en tant qu'inhibiteurs de btk
MA42376A (fr) Dérivés d'oxopyridine substitués
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
MA37888A1 (fr) Composition pharmaceutique enrobée contenant du régorafenib
MA33608B1 (fr) Composition pharmaceutique, forme galenique, procede pour leur preparation, methodes de traitement et leurs utilisations
MA32226B1 (fr) Compositions et leurs procedes de preparation et d'utilisation
NZ628096A (en) Cycloalkyloxy-n-substituted-benzenesulfonamide derivatives and uses thereof for treatment or prevention of pain
MY176421A (en) Substituted aminopyrimidine compounds and methods of use
MA34083B1 (fr) Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques
MA38391A1 (fr) Dérivés de pyridinyl et triazolone pyridinyl de fusion
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
WO2007003330A3 (fr) Forme dosifiee pharmaceutique contenant une association de principes actifs de nifedipine et/ou de nisoldipine et un antagoniste de l'angiotensine-ii
MA37742A1 (fr) Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA39165A1 (fr) Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
MA37721B1 (fr) Formes pharmaceutiques contenant du 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phényl]-1,3-oxazolidin-5-yl}-méthyl)-2-thiophène-carboxamide
MA38925B1 (fr) Dérivés de phénylalanine substitués
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MX2021008536A (es) Formulaciones en comprimidos de liberacion modificada que contienen inhibidores de fosfodiesterasa.
MA38215A1 (fr) Composition pharmaceutique ophtalmologique topique contenant regorafenib
MA38974A1 (fr) Formes galéniques pharmaceutiques contenant du sodium 1-[6-{morpholine-4-yl)pyrimidine-4-yl]-4-(1h-1,2,3- triazol-1-yl)-1h-pyrazol-5-olate
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions